Novo Nordisk A/S

3.6 million Medicare patients could get heart health coverage

Health
Rachel Carter

Medicare’s budget could be strained as more plans cover the costs of Wegovy. The program’s prescription drug plans could spend an additional ...

How much people are willing to spend

Health
Rachel Carter

Boxes of Wegovy made by Novo Nordisk are seen at a pharmacy in London, Britain March 8, 2024.  Hollie Adams | Reuters ...

Cramer’s Lighting Round: Arm is a buy

Technology
Michael Johnson

See Chart… Unity Software’s year-to-date stock performance. Unity Software: “I would have told you to sell the stock. But, you know what, ...

Wegovy heart health approval won’t mean broad insurance coverage yet

Health
Rachel Carter

Some employers and other health plans are still reluctant to cover Wegovy due to its hefty $1,350 monthly price tag, which they ...

Zealand Pharma soars 32% after promising weight-loss drug results

Business
Jessica Roberts

Vials move along a conveyor at the Novo Nordisk A/S production facilities in Hillerod, Denmark, on Monday, June 12, 2023. The success ...

What to know about insurance coverage for weight loss drugs and costs

Health
Rachel Carter

Many U.S. companies are grappling with health insurance coverage issues for workers when it comes to GLP-1 drugs for weight loss. Despite ...

Post-Ozempic patients may eat more calories, Deutsche Bank survey finds

Health
Rachel Carter

A customer shops in a Kroger grocery store on July 15, 2022 in Houston, Texas. Brandon Bell | Getty Images Investors have ...

Health sector themes to watch in 2024

Business
Jessica Roberts

An employee works on the production line of pharmaceutical company Zentiva in Prague, Czech Republic, May 6, 2021. David W. Cerny | ...

Pharma had a year full of firsts

Health
Rachel Carter

Soumyabrata Roy | Nurphoto | Getty Images The Alzheimer’s disease space also got plenty of attention, with the approval and launch of ...

2024 expectations for Wegovy, Ozempic, Zepbound

Health
Rachel Carter

Demand for the drugs is unlikely to slow down in 2024, especially as treatments gradually become more accessible. Much of Wall Street ...